Formononetin in Jiawei Qihuangyin inhibits podocyte epithelial–mesenchymal transition and ameliorates diabetic nephropathy via SIRT1/NF-κB axis
JWQHY exerts therapeutic effects in diabetic nephropathy by modulating the SIRT1/NF-κB signaling axis through its active compound formononetin, thereby inhibiting podocyte EMT. These findings provide mechanistic insight into the pharmacological basis of FMN and support its clinical potential in DN treatment.
Authors
- H.W. Liu
- Xufang Wu
- Huiyuan Li
- Jiaer Ke
- Yanli Zhou
- Huanhuan Chen
- Juan Li
Institutions
- Guangzhou University of Chinese Medicine (CN)
- Guangzhou University (CN)
- Guangdong Provincial Hospital of Traditional Chinese Medicine (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Molecular Immunology
- Published
- 2026-01-02
- DOI
- https://doi.org/10.1016/j.molimm.2025.12.010
- Primary Topic
- Sirtuins and Resveratrol in Medicine
- Type
- article
- Field-Weighted Citation Impact
- 0.00